TIA market seen reaching $252.62 million by 2035

Market Research Future projects the global transient ischemic attack market will grow from $146.9 million in 2025 to $252.62 million by 2035, driven by rising stroke incidence, aging populations and wider use of telehealth and advanced diagnostics. The report points to North America as the current revenue leader and highlights new opportunities in AI-enabled imaging, remote monitoring and novel anticoagulants.

Why it matters: - Transient ischemic attacks are often warning events before a full stroke, so faster diagnosis and preventive treatment can reduce long-term disability and death. - The market outlook reflects broader demand for early detection tools, remote care and therapies that can intervene before a stroke occurs. - Aging populations and rising rates of hypertension, diabetes and obesity are expanding the pool of patients at risk.

What happened: - Market Research Future projected the global transient ischemic attack market will reach $252.62 million by 2035, up from $146.9 million in 2025. - The forecast implies a 5.64% compound annual growth rate from 2025 to 2035. - The market base was estimated at $137.57 million in 2024. - The report said the growth case is being driven by stroke incidence, diagnostic advances and telehealth integration. - The report identified three major growth forces: more stroke and TIA cases worldwide, better diagnostic and predictive technologies, and wider use of remote monitoring and virtual consultations.

The details: - World Health Organization data cited in the report indicate about 15 million people suffer a stroke each year worldwide. - The report said a significant portion of those cases involve transient ischemic attacks as precursors. - Enhanced imaging, biomarker identification, portable imaging and AI-driven predictive analytics are improving speed and accuracy in TIA detection. - CT scans remain the dominant diagnostic method because they are widely available and provide quick results. - MRI is the fastest-growing diagnostic segment because of its detailed imaging capabilities. - Antiplatelet therapy is the largest treatment segment, supported by regimens such as aspirin and clopidogrel. - Anticoagulants are the fastest-growing treatment segment as drug formulations and delivery methods improve. - Atherosclerotic TIAs are the largest type segment, while embolic TIAs are the fastest-growing type segment. - Sudden weakness is the largest symptom segment. - Speech difficulties are the fastest-growing symptom segment. - Hypertension is the largest risk-factor segment. - Diabetes is the fastest-growing risk-factor segment. - North America led the market in 2024 with 68.78% of global revenue, or about $68.8 million. - Europe was valued at EUR 38.27 million in 2024. - Asia-Pacific was valued at about $25.52 million. - The Middle East and Africa reached $5.0 million in 2024. - The report linked North America's lead to stroke-prevention awareness, medical technology and supportive health policy. - The report said Europe benefits from regulatory support, healthcare funding and an aging population. - The report said Asia-Pacific growth is being supported by higher healthcare spending and infrastructure gains. - The report said MEA growth is being limited by uneven awareness and infrastructure gaps.

Between the lines: - The report frames TIA care as moving from reactive treatment to prevention-focused care. - Telehealth, AI and digital monitoring are becoming as important to this market as drugs and imaging equipment. - The competitive field appears moderately fragmented, with large drugmakers pushing into digital health and next-generation therapies. - The age wave matters: the United Nations projects the global population aged 60 and older will reach 1.4 billion by 2030, increasing the number of people vulnerable to TIAs. - Boehringer Ingelheim is advancing a novel anticoagulant trial for patients with a history of TIAs. - AstraZeneca partnered with a telehealth provider to build a digital monitoring platform for patients at risk of TIAs. - Bristol-Myers Squibb expanded a collaboration with a biotech firm to explore gene therapy for preventing recurrent TIAs.

What's next: - Market Research Future expects more investment in AI-driven diagnostics, remote monitoring, personalized antithrombotic therapy, digital care platforms and gene therapy. - The report’s 2035 outlook points to continued growth as healthcare systems put more emphasis on early intervention and stroke prevention. - The full report is available here. - A free sample can be requested here. - Customization requests are available here.